File(s) under permanent embargo

Reason: Restricted by author. A copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library, or by emailing

GILZ represents a novel checkpoint in the interferon program in SLE

posted on 09.11.2020, 02:51 by CHAMPA TUMKUR NATARAJA
Systemic Lupus Erythematosus (SLE) or lupus is a multi-system autoimmune disease that predominantly affects younger women. The treatment of lupus has scarcely changed over the last seven decades—glucocorticoids or steroids remain the most prescribed treatment in lupus. As a ‘double-edged sword’, the use of these drugs is accompanied by a litany of adverse effects that contribute to morbidity and mortality in these patients. Thus, there is a dire need for a drug that mimics the anti-inflammatory effects of steroids but without the negative metabolic effects. GILZ may represent such an alternative, potentially leading to improved outcomes for lupus patients.


Principal supervisor

Eric Francis Morand

Additional supervisor 1

Dr Sarah Jones

Additional supervisor 2

Prof Michelle Leech

Year of Award


Department, School or Centre

Medicine - Monash Health

Campus location



Doctor of Philosophy

Degree Type